GHTM

Global Health and Tropical Medicine

  • GHTM
    • Vision
    • Mission
    • Governance
    • Scientific Advisory Board
  • News
    • Outreach
    • Events
      • GHTM Sessions
      • Workshops
    • Articles
    • Jobs
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases and pathogens
      • IHC – Individual health care
    • Research in numbers
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases and pathogens
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Technical / administrative support
  • Publications
  • Education
    • Master Theses
    • PhD Theses
  • Services
Home / Archives for Novo C

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells

  • Autores: Loureiro LR, Feldmann A, Bergmann R, Koristka S, Berndt N, Arndt C, Pietzsch J, Novo C, Videira P, Bachmann M
  • Ano de Publicação: 2018
  • Journal: Blood Cancer Journal
  • Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127150/

Ler mais

Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids

  • Autores: Loureiro LR, Sousa DP, Ferreira D, Chai W, Lima L, Pereira C, Lopes CB, Correia VG, Silva LM, Li C, Santos LL, Ferreira JA, Barbas A, Palma AS, Novo C, Videira PA
  • Ano de Publicação: 2018
  • Journal: Scientific Reports
  • Link: https://www.nature.com/articles/s41598-018-30421-w

Incomplete O-glycosylation is a feature associated with malignancy resulting in the expression of truncated glycans such as the sialyl-Tn (STn) antigen. Despite all the progress in the development of potential anti-cancer antibodies, their application is frequently hindered by low specificities and cross-reactivity. In this study, a novel anti-STn monoclonal antibody named L2A5 was developed by hybridoma […]
Ler mais

Thermal and magnetic properties of chitosan-iron oxide nanoparticles

  • Autores: Borges P, Coutinho JT, Ferreira IMM, Laia C, Machado D, Novo C, Pereira LCJ, Soares PIP
  • Ano de Publicação: 2016
  • Journal: Carbohydrate Polymers
  • Link: https://www.sciencedirect.com/science/article/pii/S0144861716305008

Chitosan is a biopolymer widely used for biomedical applications such as drug delivery systems, wound healing, and tissue engineering. Chitosan can be used as coating for other types of materials such as iron oxide nanoparticles, improving its biocompatibility while extending its range of applications. In this work iron oxide nanoparticles (Fe3O4 NPs) produced by chemical […]
Ler mais

Iron oxide nanoparticles stabilized with a bilayer of oleic acid for magnetic hyperthermia and MRI applications

  • Autores: Borges JP, Carvalho A, Coutinho JT, Ferreira IMM, Laia CAT, Novo C, Pereira LCJ, Soares PIP
  • Ano de Publicação: 2016
  • Journal: Applied Surface Science
  • Link: https://www.sciencedirect.com/science/article/pii/S0169433216309709

Iron oxide nanoparticles (Fe3O4, IONPs) are promising candidates for several biomedical applications such as magnetic hyperthermia and as contrast agents for magnetic resonance imaging (MRI). However, their colloidal stability in physiological conditions hinders their application requiring the use of biocompatible surfactant agents. The present investigation focuses on obtaining highly stable IONPs, stabilized by the presence […]
Ler mais

Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment.

  • Autores: Borges JP, Dias SJ, Ferreira IM, Novo C, Soares PI
  • Journal: Mini-Reviews in Medicinal Chemistry
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Doxorubicin+vs.+ladirubicin%3A+methods+for+improving+osteosarcoma+treatment

Osteosarcoma is the most common primary bone tumor in children and adolescents, with a 5-year disease free survival rate of 70%. Current chemotherapy regimens comprise a group of chemotherapeutic agents in which doxorubicin is included. However, tumor resistance to anthracyclines and cardiotoxicity are limiting factors for its usage.
Ler mais

  • 1
  • 2
  • 3
  • 4
  • Next Page »

About GHTM

GHTM is a R&D Center that brings together researchers from IHMT with a track record in Tropical Medicine and International/Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal
+351 213 652 600
+351 213 632 105

  • Facebook
  • YouTube

Subscribe Newsletter

  • How to get to GHTM/IHMT
  • GHTM Sessions
  • Research Groups
  • Cross-cutting issues
© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013